オプションチェーンは、TPGの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、TPGの市場センチメントを評価します。.

TPG (NASDAQ:TPG) 株価情報, オプションチェーン

TPG Inc is an alternative asset firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, and Market Solutions. TPG aims to build dynamic products and options for its clients while also instituting discipline and operational excellence across the investment and performance of its portfolio.

TPG Inc

TPG Pace Tech Opportunities II Corp

TPG Telecom Ltd

TOP GLOVE CORP BHD ORD by Top Glove Corp.

Top Glove Corp Bhd

TPG Inc. - 6.950% Fixed-Rate Junior Subordinated Notes due 2064

Barclays analyst George Wang initiates coverage on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Overweight rating and announces Price Target of $91.

News

Price Target

Initiation

Analyst Ratings

Barclays Initiates Coverage On Celestica with Overweight Rating, Announces Price Target of $91

Guidance

NeoGenomics Reiterates FY24 Revenue Outlook In The Range Of $655M-$667M; Raises Adjusted EBITDA Guidance From $33M-$37M To $37M-$40M

AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) reported quarterly sales of $805.86 million which missed the analyst consensus estimate of $809.30 million by 0.43 percent. This is a 0.23 percent increase over sales of $804.03 million the same period last year.

Earnings

Earnings Misses

AHCO

AdaptHealth Q3 Sales $805.86M Miss $809.30M Estimate

Biotech

Health Care

General

TRDA

Entrada Therapeutics Says Cash Runway Expected Into 2027 With $449M In Cash, Cash Equivalents And Marketable Securities As Of September 30, 2024

Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.78) by 55.13 percent. The company reported quarterly sales of $19.57 million which beat the analyst consensus estimate of $12.32 million by 58.83 percent. This is a 55.25 percent decrease over sales of $43.73 million the same period last year.

Entrada Therapeutics Q3 2024 GAAP EPS $(0.35) Beats $(0.78) Estimate, Sales $19.57M Beat $12.32M Estimate

By <a href="https://roboforex.com/beginners/analytics/forex-forecast/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_05112024&amp;utm_content=analysis&amp;utm_term=forecast" style="color:#0563c1; text-decoration:underline">RoboForex Analytical Department</a>
EURUSD remains poised around 1.0878 as markets brace for the outcome of the highly anticipated US presidential election. With the world watching, the direction of the major currency pair will hinge significantly on the election results, where a victory for Donald Trump is likely to bolster the USD, potentially leading to a notable increase. Conversely, a win for Kamala Harris could see the USD decline by an average of 1-2%.
The impending volatility is not solely due to the election but amplified by the upcoming Federal Reserve meeting scheduled for Wednesday. The Fed is anticipated to cut interest rates slightly by 25 basis points. Market participants are keenly awaiting any forward guidance from the Fed, particularly with expectations leaning towards another rate reduction in December.
While significant economic data releases are also expected, these pivotal events may overshadow their impact.
<h3>Technical Analysis Of EUR/USD</h3>
<a href="https://www.benzinga.com/files/u117641/eurusdh4_71.png"><img alt="" src="https://www.benzinga.com/files/u117641/eurusdh4_71.png" style="height:280px; width:624px" /></a>
The EURUSD market has completed a growth structure reaching 1.0913, considered part of a third growth wave targeting 1.0950. After this target is achieved, a retraction to 1.0860 is anticipated, potentially forming a broad consolidation range around this level. Technical indicators, such as the MACD, suggest an upward trajectory, reinforcing the possibility of reaching 1.0960 before a corrective pullback to 1.0860.
<a href="https://www.benzinga.com/files/u117641/eurusdh1_72.png"><img alt="" src="https://www.benzinga.com/files/u117641/eurusdh1_72.png" style="height:280px; width:624px" /></a>
Support at 1.0872 has spurred the development of a growth impulse towards 1.0900, which is expected to be tested soon. Breaching this level could extend the growth wave towards 1.0950. The Stochastic oscillator supports this short-term forecast, indicating upward momentum with its signal line targeting the upper echelons around 80.
Disclaimer
Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Technicals

Forex

Markets

Trading Ideas

EUR/USD Stabilises As US Presidential Election Unfolds

Leerink Partners analyst Mani Foroohar initiates coverage on Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) with a Outperform rating and announces Price Target of $17.

CAMP

Leerink Partners Initiates Coverage On Camp4 Therapeutics with Outperform Rating, Announces Price Target of $17

NURO

NeuroMetrix Reports Q3 2024 Sales Of $0.6M Vs. $1.2M YoY, With EPS Loss Of $(0.75) Compared To ($1.66) YoY

As of month-end, the Company operated approximately 185,000 bitcoin miners in data centers for both self-mining and hosting, representing a total energized hash rate of 21.8 EH/s. &nbsp;

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific Says It Earned 369 Bitcoin In October From Its Owned Fleet Of Miners Vs. 345 In September

Select October 2024 Highlights
<ul>
<li>Record total average daily volume ("ADV") of $46.2 billion increased 40% compared to the prior year, and increased 2% compared to September 2024. These strong results were driven by total credit ADV of $15.0 billion, representing an increase of 19% compared to the prior year, and a decrease of 9% compared to September 2024. Record total rates ADV of $31.2 billion, which increased 54% compared to the prior year, and increased 9% compared to September 2024 levels, also contributed to the strong performance in October 2024.</li>
<li>Record total trading volume of $1.0 trillion on the platform increased 47% compared to the prior year, and increased 12% compared to September 2024.</li>
</ul>

MKTX

MarketAxess Announced Trading Volume For October 2024 With Total Average Daily Volume Of $46.2B, Up 40% YoY And +2% Compared To September 2024

NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.01 by 400 percent. The company reported quarterly sales of $167.824 million which beat the analyst consensus estimate of $167.010 million by 0.49 percent. This is a 10.44 percent increase over sales of $151.954 million the same period last year.

Earnings Beats

NeoGenomics Q3 2024 Adj. EPS $0.05 Beats $0.01 Estimate, Sales $167.824M Beat $167.010M Estimate

Leerink Partners analyst Christopher Liu downgrades IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) from Outperform to Market Perform and lowers the price target from $41 to $27.

Downgrades

IDYA

Leerink Partners Downgrades IDEAYA Biosciences to Market Perform, Lowers Price Target to $27

Pseudonymous crypto analysts DonAlt and CryptoCred explored Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price trends and the impact of <a href="https://www.benzinga.com/news/24/11/41733346/obamas-former-campaign-manager-alarmed-by-early-voting-numbers-as-harris-trump-fight-close-battle-re">Tuesday&#8217;s presidential election</a>.
Bitcoin's Expected Trajectory
In the latest &#8216;Technical Roundup&#8217; <a href="https://www.youtube.com/watch?v=IhonU0vEFQE&amp;pp=ygURdGVjaG5pY2FsIHJvdW5kdXA%3D">episode</a>, DonAlt noted Bitcoin's recent surge to close to its all-time high before retreating below $70,000, calling the monthly close "catastrophic" after a key resistance retest.
He projected $49,000 as the first support level in the short term, with more robust support near $35,000 on a monthly timeframe, and in an extreme scenario, a possible drop to $16,000.
DonAlt attributes recent sluggish crypto market activity to positioning ahead of a potential Trump victory. He <a href="https://x.com/CryptoDonAlt/status/1853452002983813251">cautioned</a> on X that a Trump win might bring only modest short-term upside for Bitcoin, while a loss could trigger a sell-off, with a Harris win potentially causing an even steeper decline. Emphasizing flexibility, DonAlt highlighted the need for strategic preparation as election results unfold.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41720318/bitcoin-on-the-evening-of-the-election-heres-how-it-performed-in-2012-2016-and-2020">Bitcoin On The Evening Of The Election—Here&#8217;s How It Performed In 2012, 2016 And 2020</a>
Ethereum's Play
DonAlt also commented on Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) underperformance relative to Bitcoin, stressing the dependency of ETH/BTC strength on Bitcoin's movement. He shared his open position in a SOL/BTC trade.
Given the election uncertainty, DonAlt concluded, "I'm not going to trade in the next weeks, maybe months," stressing the importance of caution in the current environment.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41709166/bitcoin-to-hit-100-000-by-january-2025-could-black-hole-effect-push-the-largest-crypto-to-">Bitcoin To Hit $100,000 By January 2025? Could &#8216;Black Hole Effect&#8217; Push The Largest Crypto To Never-Before-Seen Levels</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Veteran Traders Share 'Presidential Election Crypto Trading Roadmap,' Predict Heavy Volatility

<a href="https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona" title="https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona">https://www.aboutamazon.com/news/transportation/amazon-drone-delivery-arizona</a>

AMZN

Amazon Says Customers In West Valley Phoenix Metro Area Now Receiving Prime Air Drone Deliveries

Coloplast (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLPBY#OTC">CLPBY</a>) reported quarterly earnings of $0.08 per share. This is unchanged from the same period last year. The company reported $1.02 billion in sales this quarter. This is a 12.64 percent increase over sales of $909.09 million the same period last year.

CLPBY

Coloplast Q4 EPS $0.08, Same YoY, Sales $1.02B Up From $909.09M YoY

RNAZ

Transcode Therapeutics Has Received Notice From The Nasdaq Stock Market To Grant Transcode's Request To Continue Its Listing On The Nasdaq Stock Market Subject To Certain Conditions To Regain Compliance

The Company anticipates releasing its financial results for the six months ended June 30, 2024, by the end of November.
 &nbsp;

HUBC

HUB Security Says Making Progress On All Fronts, With Steady Advancement In Existing Contracts; Aims To Strategically Position Itself For Significant Penetration Into US Market In Q1 2025

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the financials sector.
<h3 class="wp-block-heading">Lincoln National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>)</h3>
<ul>
<li>Dividend Yield: 5.47%</li>
<li>Wells Fargo analyst Elyse Greenspan maintained an Equal-Weight rating and raised the price target from $28 to $29 on Oct. 10. This analyst has an accuracy rate of 75%.</li>
<li>Barclays analyst Alex Scott maintained an Equal-Weight rating and raised the price target from $35 to $36 on Oct. 8. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On Oct. 31, Lincoln National posted better-than-expected quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1">latest LNC news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="918" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24.png" alt="" class="wp-image-629784" style="width:694px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044515/image-24-768x704.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">Heritage Commerce Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>)</h3>
<ul>
<li>Dividend Yield: 5.44%</li>
<li>Piper Sandler analyst Andrew Liesch maintained an Overweight rating and raised the price target from $10 to $12 on July 26. This analyst has an accuracy rate of 78%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Wood Lay maintained an Outperform rating and increased the price target from $10.5 to $11.5 on July 26. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Oct. 24, Heritage Commerce posted in-line quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1">latest HTBK news.</a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25.png" alt="" class="wp-image-629786" style="width:655px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044644/image-25-768x715.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Columbia Banking System, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>)</h3>
<ul>
<li>Dividend Yield: 5.19%</li>
<li>Truist Securities analyst Brandon King maintained a Hold rating and raised the price target from $28 to $30 on Oct. 28. This analyst has an accuracy rate of 81%.</li>
<li>RBC Capital analyst Jon Arfstrom maintained a Sector Perform rating and increased the price target from $29 to $31 on Oct. 25. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On Oct. 24, Columbia Banking System posted better-than-expected quarterly results.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"> trend in COLB stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26.png" alt="" class="wp-image-629787" style="width:614px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05044902/image-26-768x698.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41735699/archer-daniels-midland-yum-brands-and-3-stocks-to-watch-heading-into-tuesday">Archer-Daniels-Midland, Yum! Brands And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>

Dividends

Pre-Market Outlook

COLB

HTBK

Wall Street's Most Accurate Analysts Spotlight On 3 Financial Stocks Delivering High-Dividend Yields

Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 14.55 percent increase over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $4.89 million which beat the analyst consensus estimate of $3.35 million by 46.09 percent. This is a 47.94 percent increase over sales of $3.31 million the same period last year.

STOK

Stoke Therapeutics Q3 2024 GAAP EPS $(0.47) Beats $(0.54) Estimate, Sales $4.89M Beat $3.35M Estimate, $269.2M In Cash, Cash Equivalents, And Marketable Securities

Keybanc analyst Aleksey Yefremov maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Overweight and lowers the price target from $164 to $154.

ENTG

Keybanc Maintains Overweight on Entegris, Lowers Price Target to $154

Shares of contact lens supplier Bausch + Lomb ($BLCO) are surging in today's trading amid news of a potential acquisition. According to an exclusiv...

M&A News: TPG and Blackstone Could Eye Joint Bid for Bausch + Lomb (NYSE:BLCO)

REITs Rally As Earnings Begin

Banks and private credit firms are competing to provide at least $5B of debt financing to help fund a potential buyout of Bausch + Lomb (BLCO), Jea...

Banks competing to fund possible Bausch + Lomb buyout, Bloomberg says

TPG Non-GAAP EPS of $0.45 in-line

TPG cuts dividend by 9.5%

TPG Inc. (TPG) Q3 2024 Earnings Call Transcript

Tpg Inc Class A ( ($TPG) ) has released its Q3 earnings. Here is a breakdown of the information Tpg Inc Class A presented to its investors. TPG Inc...

TPG Inc. Reports Strong Third Quarter Growth

In a report released today, Kyle Voigt from KBW maintained a Hold rating on TPG (TPG – Research Report), with a price target of $62.00. The company...

KBW Sticks to Their Hold Rating for TPG (TPG)

Capture Growth In Alternative Investments With TPG Stock

Companies in the Financial sector have received a lot of coverage today as analysts weigh in on TPG (TPG – Research Report) and Corebridge Financia...

Analysts Conflicted on These Financial Names: TPG (TPG) and Corebridge Financial, Inc. (CRBG)

AGNC

AGNCL

AGNCM

AGNCN

AGNCO

AGNCP

BLCO

BLDG

BXMT

CHCT

CRBG

CUBE

DHCNI

DHCNL

EQIX

FREL

GQRE

HAUS

HAUZ

HOMZ

IFGL

ILPT

INDS

INVH

IRET

KBWY

MORT

NAIL

NETL

NURE

OPINL

PFFR

PINE

PLDGP

PPTY

RDOG

REET

REGCO

REGCP

REIT

REXR

RIET

ROOF

SBAC

SBRA

SCHH

SRVR

STWD

USRT

VIOO

VRAI

WELL

XLRE

Press Releases

Homrich Berg Announces New Minority Investment Partner TPG Growth

TPG to Acquire AT&T's 70% Stake in DIRECTV

Entertainment

DIRECTV to Acquire EchoStar's Video Distribution Business, Including DISH TV and Sling TV

Creative Planning Announces Strategic Investment from TPG Capital

KBRA Assigns Rating to TPG Twin Brook Capital Income Fund's $400 Million Senior Unsecured Notes Due in 2028 and 2029

TPG to Announce Third Quarter 2024 Financial Results and Host Investor Call

TPG RE Finance Trust, Inc. Announces Third Quarter 2024 Earnings Release and Conference Call Dates

TPG Names Recently Established Entertainment Company "Initial Group" and Acquires Grandview in Partnership with Untitled Entertainment

TPG RE Finance Trust, Inc. Reports Operating Results for the Quarter Ended September 30, 2024

Comments

TPG

TPG (TPG) オプション

TPG (NASDAQ:TPG) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル